Vážený uživateli, je nám líto, ale Váš prohlížeč nepodporuje plné zobrazení webu. Doporučujeme Vám přejít na jeho aktuálnější verzi (MS Edge) nebo na některý z nejčastějších prohlížečů (Chrome, Firefox, Safari).

Biotech market remains low, and no oncology IPO was completed in last three months

SOTIO Biotech

7/7/2022 | 4 minuty čtení

April was the cruelest month for biotech so far and the stocks remain low. However, big pharma companies are still resisting temptation for biotech M&A spree until prices drop further. The IPO market is also dead, with only 12 IPOs completed this year and no oncology IPO in last three months.

Monthly market moves of selected competitors compared to NASDAQ Biotechnology Index (NBI)

Area	Company	Ticker	Price range $	Δ Price		MktCap $m	ΔMktCap $m
ADC	ADC Therapeutics	ADCT	6.45 – 12.26	-42	%	525	-378
	Immunogen	IMGN	3.47 – 5.16	-24	%	807	-258
	Mersana Therapeutics	MRSN	2.84 – 3.96	-4	%	324	-12
	Seagen	SGEN	108.81– 146.55	4	%	24 975	860
IL15 / 2	Alkermes	ALKS	26.40 – 30.54	3	%	4 878	163
	ImmunityBio	IBRX	2.68 – 4.40	4	%	1 496	52
	Nektar Therapeutics	NKTR	3.39 – 4.66	-16	%	648	-121
	Xencor	XNCR	22.23 - 26.03	-11	%	1 330	-154
CAR-T	Allogene Therapeutics	ALLO	6.78 – 9.43	-5	%	1 139	-51
	Autolus Therapeutics	AUTL	2.22 – 3.29	-12	%	249	-35
	Bellicum Pharma	BLCM	1.35 – 1.70	-10	%	12	-1
	Mustang Bio	MBIO	0.64 – 0.76	-13	%	67	-8
Other	Arcus Biosciences	RCUS	17.23 – 25.33	-22	%	1 359	-342
	Immutep	IMMP	2.20 – 2.97	30	%	222	51
	Clovis Oncology	CLVS	0.63 – 2.10	-65	%	101	-184

ADC Therapeutics

ADCT reported net loss of $17 million, or a net loss of $0.22 per share, for Q1 2022. This compares to a net loss of $52 million, or a net loss of $0.67 per share, for the same quarter in 2021.

Immunogen

Immunogen said that FDA accepted and filed the BLA for mirvetuximab soravtansine monotherapy in patients with FRα-high platinum-resistant ovarian cancer who have been previously treated with 1 to 3 prior systemic treatments. The application has been granted Priority Review designation.

Mersana Therapeutics

Mersana announced that FDA has granted orphan drug designation to XMT-2056, the company’s lead Immunosynthen STING-agonist ADC, for the treatment of gastric cancer.

Seagen

Seagen announced positive topline results from the pivotal phase 2 MOUNTAINEER trial investigating Tukysa in combination with trastuzumab in patients with previously treated HER2-positive metastatic CRC. Data from this trial will form the basis of a planned sNDA to FDA under the FDA’s Accelerated Approval Program. Results showed a 38.1% confirmed ORR. The median DOR was 12.4 months.

Alkermes

Alkermes announced the acceptance of four abstracts related to nemvaleukin, the company's IL-2 variant immunotherapy at ASCO. The final dataset from the phase 1/2 ARTISTRY-1 trial, evaluating nemvaleukin as monotherapy and in combination with pembrolizumab, will be shared in an oral presentation. In addition, trial-in-progress posters from ongoing ARTISTRY-3 trial and the potential registration-enabling studies ARTISTRY-6 and ARTISTRY-7 will be presented.

ImmunityBio

ImmunityBio has submitted BLA to FDA for N-803, IL-15 superagonist, plus Bacillus Calmette-Guérin (BCG) for the treatment of BCG-unresponsive non-muscle invasive bladder carcinoma in situ with or without Ta or T1 disease. The BLA is supported by the results of ImmunityBio’s studies in bladder cancer including the pivotal QUILT 3032 study.

Nektar Therapeutics

Nektar came out with a quarterly loss of $0.49 per share versus estimate of a loss of $0.72. This compares to loss of $0.68 per share a year ago. The company said the workforce reduction is on track.

Xencor

Xencor reported initial dose-escalation data from the Phase 1 study evaluating XmAb®104, a PD-1 x ICOS bispecific antibody, in patients with advanced solid tumors (DUET-3). These results will be presented at ASCO. XmAb104 has been well tolerated and is exhibiting a distinct safety profile compared to other clinical ICOS programs, which, along with early anti-tumor activity in patients, supports its evaluation in expansion cohorts.

Allogene Therapeutics

Allogene presented preclinical findings evaluating the characteristics and function of donor-derived allogeneic CAR T cells. Data showed that cells from a diverse set of younger donors had improved characteristics and better in vitro anti-tumor activity compared to cells from older donors. The study also showed that cells from patients with certain cancers generally performed suboptimally based on functional assays and often could not be used to generate viable CAR T therapies.

Autolus Therapeutics

Autolus reported net loss of $37 million, or $0.41 per share, for 1Q 2022, compared to $33 million, or 0.53 per share, for the same period in 2021.

Bellicum Pharmaceuticals

Bellicum reported a net loss of $8 million for the first quarter 2022, compared to a net loss of $11 million for first quarter 2021.

Mustang Bio

Mustang announced that results from the follicular lymphoma cohort of the ongoing Phase 1/2 trial of MB-106, a CD20-targeted, autologous CAR T cell therapy, in patients with relapsed or refractory B-cell NHL and CLL were selected for an oral presentation at the EHA.

Arcus Biosciences

Arcus reported net loss was $68 million for the three months ended March 31, 2022, compared to a net loss of $72.6 million for the same period in the prior year.

Immutep

Immutep announced new interim data from Part A of the Phase 2 TACTI-002 trial in 1st line NSCLC has been published in an abstract at ASCO 2022. The oral presentation will present data from all 114 patients with a more recent data cut off and will be the subject of a further announcement from the company.